BridgeBio to present positive Phase 3 trial results of oral infigratinib for children with achondroplasia at ICCBH 2026.

BridgeBio Pharma announced it will share additional positive data from its global Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia at the ICCBH 2026 conference in Montreal. The presentation will highlight the drug's potential to treat this genetic bone growth disorder, alongside other research on quality of life and early intervention. This data could advance treatment options for children with achondroplasia, a condition with limited therapies. The event runs June 27-30, 2026, with multiple presentations from BridgeBio experts.